With a disproportionately large number of patients willing to participate in global studies, Canada’s world-class researchers and diverse patient population, trial cost efficiency, robust health authority with reliable process times, consistent data quality, and national therapeutic expertise in oncology make it an attractive country for enrollment of clinical trial patients in global oncology clinical research studies.
Leading Clinical Trial Productivity
Clinical research is increasingly intricate due to complex protocols, demanding data collection needs, and constricted study timelines. As a result, the number of clinical trials being initiated in some regions now exceeds the capacity for clinical research sites to conduct these trials.
Capturing 4% of global clinical trials, Canada is fourth in its number of clinical trials sites and is the G7 leader in clinical trial productivity (number of trials/population). The nation is recognized internationally for the quality and expertise of its research clinicians, many of whom are globally renowned for major medical discoveries and innovations, and for its ability to conduct clinical research in complex therapeutic areas with diverse population bases.
Recruitment Success
The recruitment success rate in clinical trials for this country is reported to be 98%, with sites in Canada that have as much as 22% of their total patient population participating in clinical trials.
Canada boasts a high percentage of foreign-born citizens. Making a diverse population combined with a universal healthcare
system for all Canadian citizens a compelling opportunity for cutting-edge oncology biotechs striving to ensure their global clinical studies get the right mix of trial participants.
Projections to 2036 indicate people of color and Aboriginal / Indigenous peoples will make up about one third of the total Canadian population (34.4%). This marks a 9% of total population increase on average for each 15 year interval from 2001.
In addition, Canada’s vast disease treatment networks allow PIs to coordinate research across multiple centers of expertise. These networks use provincial and national patient databases maintained by government agencies such as Cancer Care Ontario to connect medical experts and patients to clinical trials; in turn, Canadian PIs are easily able to screen and find suitable patients for participation in their global studies.
Universal Healthcare
The advantage of universal health care in Canada means all citizens receive coverage for basic health care services, and no legal resident is denied care. Access for Canadian citizens is granted regardless of status, income, employment, health, or age. The administration of Canadian healthcare is on a province-by-province basis, and the entire health care system is paid for by taxes.
Without worries about cost or insurance restrictions, in general Canadian residents seek medical care more readily than their counterparts in privately funded healthcare systems do. Furthermore, nearly two thirds of Canadians (78%) live within 160 kilometers (about 100 miles) of the U.S. border. This makes geographical access to publicly funded healthcare relatively easy for most of the population. As a result, Canadian PIs in cancer centers across the country have access to a large patient population relative to the country’s population size.
Recognized International Standards
Canada has recognized international standards of Good Clinical Practice, including the standards of conduct developed by the International Conference on Harmonisation (ICH).
As a result, data from clinical trials conducted in Canada is generally viewed with confidence by International regulatory authorities, including the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA).
Robust & Efficient Regulatory
With strong infrastructure like that in the EU, yet unlike Europe’s slow regulatory frameworks and higher costs that can limit recruitment, Health Canada oversight provides efficient regulatory processes for the approval of clinical trials in a consistently timely manner.
A 30-day CTA default review period applies in Canada. If questions are raised during the dossier review a response must be provided within two calendar days. And by way of comparison, unlike the US, there is no clinical hold period in Canada. The review period is always 30 days, while in some European countries the review period can be as long as 60 days or more, and in the U.S. it can vary unpredictably. This Canadian standard of a 30-day regulatory review period facilitates ethics review submission planning and speeds up clinical trial start times over other regions for clinical research conducted in this country.
Top-Quality Data
Canada is associated with the production of top-quality data in global studies. Success in this department can be attributed in part to the Canadian government’s ongoing financial support which is helping staff Canada’s oncology clinical research centers. With top global talent that foster this country’s solid reputation for research in clinical medicine, biomedicine, and science and technology.
Best Therapeutic Expertise for the Region
Unsurprisingly, enrollment success can vary from study-to-study, which is why it is vital for clinical trial sponsors to be selective about who they partner with for recruitment to their global studies. Specialized CROs with local expertise that can leverage the disease treatment networks effectively are often most successful at connecting Canadian PIs to the most relevant studies for the patient population they serve.
Mobilizing an expert Canadian team significantly enhances study start-up and overall performance for Sponsor’s oncology clinical trials in the country. In keeping with the targets shared with its Sponsors, the Scimega team delivers consistent clinical trial start-up times 50% faster than the average for other countries on the continent, with trial sites often among top enrollers in global oncology studies.
More than ever Drug Developers want access to sites that can deliver on their promises of rapid FPI (first patient in study) and patient enrollment milestones. They need a CRO with established site relationships in Canada that can provide impeccable data, swift, accurate study feasibility and viability assessments, with strong CTAs in place with sites to further facilitate site start-up times.
Scimega is a Canadian niche oncology CRO that serves medium size and smaller biotech companies in clinical development of cutting-edge oncology therapies in Canada. We consistently deliver our services with a strategic focus on Sponsor program success, and our team’s ability to engage oncologists and site teams at the highest level is unparalleled.
LEAN processes that ensure high-quality, and operation oversight of CRA activities and continuous internal QA activities is the gold standard with Scimega. And of course, our steady and high enrollments rates are a stand-out thanks to the selection of the right sites for your study design.
Scimega’s constant audit readiness and key metrics performance clearly reflects the caliber of combined skill and service this team of oncology experts consistently delivers. Scimega works hard at working smarter every year now for close to three decades.
Contributed by: Julie Martin, President & CEO












